** Shares of biotech firm ImmunityBio IBRX.O rise 2.2% to $6.81 premarket

** Co says it secured $100 million in new financing to support international expansion and drug development

** $75 million is non-dilutive funding from Oberland Capital under an existing deal; royalty payback rate rises modestly, cap unchanged – IBRX

** Separate $25 million of debt converted into ~4.6 million common shares by Nant Capital, cutting overall debt – IBRX

** Co says funds to help expand sales of Anktiva, a cancer immunotherapy for a type of bladder cancer, approved or authorized in ~34 countries

** Shares down ~23% in 2025